Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Updated biographies for board candidates at the upcoming Annual General Meeting ...

Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for use in patients with prostate cancer.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Telix’s next-generation PSMA-PET imaging agent for prostate cancer, Gozellix receives US FDA approves: Melbourne, Australia Monday, March 24, 2025, 17:00 Hrs [IST] Telix, a biop ...

On Friday the company said the FDA had approved its gallium isotope-based Gozellix, for positive emission tomography (PET) ...

The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...